Nct00105300

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

PDF) New therapeutic approach in inflammatory bowel disease

PDF) New therapeutic approach in inflammatory bowel disease

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Retrospective Evaluation of the Safety and Effect of Adalimumab

Retrospective Evaluation of the Safety and Effect of Adalimumab

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Genetic Markers Predict Primary Non-Response and Durable Response To

Genetic Markers Predict Primary Non-Response and Durable Response To

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Adalimumb sustains clinical remission and overall clinical benefit

Adalimumb sustains clinical remission and overall clinical benefit

Biologics in General Medicine | J  Salfeld | Request PDF

Biologics in General Medicine | J Salfeld | Request PDF

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current

Postoperative outcomes in vedolizumab-treated Crohn's disease

Postoperative outcomes in vedolizumab-treated Crohn's disease

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Adalimumab is effective in long-term real life clinical practice in

Adalimumab is effective in long-term real life clinical practice in

A British Society of Paediatric Gastroenterology, Hepatology and

A British Society of Paediatric Gastroenterology, Hepatology and

Frequency and predictors of loss of response to biological therapy

Frequency and predictors of loss of response to biological therapy

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Interleukin-15 and Its Soluble Receptor Mediate the Response to

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

Comparable outcomes of the consistent use versus switched use of

Comparable outcomes of the consistent use versus switched use of

PDF) Adalimumab in clinical practice  Outcome in 70 rheumatoid

PDF) Adalimumab in clinical practice Outcome in 70 rheumatoid

The tolerance and efficacy of a postponed retreatment with

The tolerance and efficacy of a postponed retreatment with

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Anti-TNF-alpha treatment strategies: results and clinical

Anti-TNF-alpha treatment strategies: results and clinical

Oral administration of an ethanolic extract of Hypericum

Oral administration of an ethanolic extract of Hypericum

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Adalimumab is effective in long-term real life clinical practice in

Adalimumab is effective in long-term real life clinical practice in

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Performance of Crohn's disease Clinical Trial Endpoints based upon

Performance of Crohn's disease Clinical Trial Endpoints based upon

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

The use of adalimumab in the management of refractory Crohn's

The use of adalimumab in the management of refractory Crohn's

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Efficacy and safety of adalimumab in patients with psoriasis

Efficacy and safety of adalimumab in patients with psoriasis

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

Dietary Therapy With the Crohn's Disease Exclusion Diet is a

Biologic Therapies and Risk of Infection and Malignancy in Patients

Biologic Therapies and Risk of Infection and Malignancy in Patients

Long-term outcome of adalimumab therapy for ulcerative colitis with

Long-term outcome of adalimumab therapy for ulcerative colitis with

Adalimumab induction therapy for Crohn disease previously treated

Adalimumab induction therapy for Crohn disease previously treated

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing

Sequential use of biologics in the treatment of moderate-to-severe

Sequential use of biologics in the treatment of moderate-to-severe

Severe Myalgia Associated with Adalimumab Treatment in a Patient

Severe Myalgia Associated with Adalimumab Treatment in a Patient

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Long-term durability of response to adalimumab in Crohn's disease

Long-term durability of response to adalimumab in Crohn's disease

Individual medicine in inflammatory bowel disease: Monitoring

Individual medicine in inflammatory bowel disease: Monitoring

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Selecting appropriate anti-TNF agents in inflammatory bowel disease

Selecting appropriate anti-TNF agents in inflammatory bowel disease

Efficacy and safety of adalimumab versus infliximab in patients

Efficacy and safety of adalimumab versus infliximab in patients

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

A Test-based Strategy Is More Cost Effective Than Empiric Dose

A Test-based Strategy Is More Cost Effective Than Empiric Dose

Efficacy and safety of adalimumab for the Crohn's disease: A

Efficacy and safety of adalimumab for the Crohn's disease: A

W1219 Appropriateness of Therapy for Active Crohn's Disease: Results

W1219 Appropriateness of Therapy for Active Crohn's Disease: Results

Health-economic analysis: Cost-effectiveness of scheduled

Health-economic analysis: Cost-effectiveness of scheduled

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Predictors of Infliximab Failure After Azathioprine Withdrawal in

Cost-effectiveness of biological treatment sequences for fistulising

Cost-effectiveness of biological treatment sequences for fistulising

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

Adalimumab for Crohn's disease with intolerance or lost response to

Adalimumab for Crohn's disease with intolerance or lost response to

Efficacy and Safety Profile of Anti-Tumor Necrosis Factor-α Versus

Efficacy and Safety Profile of Anti-Tumor Necrosis Factor-α Versus

Loss of Response and Requirement of Infliximab Dose Intensification

Loss of Response and Requirement of Infliximab Dose Intensification

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Health-economic analysis: Cost-effectiveness of scheduled

Health-economic analysis: Cost-effectiveness of scheduled

Systematic review: The short-term and long-term efficacy of

Systematic review: The short-term and long-term efficacy of

Cost-effectiveness of biological treatment sequences for fistulising

Cost-effectiveness of biological treatment sequences for fistulising

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Use of a third anti-TNF after failure of two previous anti-TNFs in

Use of a third anti-TNF after failure of two previous anti-TNFs in

Review article: a clinician's guide for therapeutic drug monitoring

Review article: a clinician's guide for therapeutic drug monitoring

Loss of Response and Need for Adalimumab Dose Intensification in

Loss of Response and Need for Adalimumab Dose Intensification in

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

The Value of Vedolizumab as Rescue Therapy in Moderate-Severe

The Value of Vedolizumab as Rescue Therapy in Moderate-Severe

Unresolved issues in identifying and overcoming inadequate response

Unresolved issues in identifying and overcoming inadequate response

Efficacy and safety of adalimumab for the Crohn's disease: A

Efficacy and safety of adalimumab for the Crohn's disease: A

Predictors of dose escalation of adalimumab in a prospective cohort

Predictors of dose escalation of adalimumab in a prospective cohort

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

The future of inflammatory bowel disease management: Combining

The future of inflammatory bowel disease management: Combining

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

T1704 Cytokine Network in Rectal Mucosa in Perianal Crohn's Disease

Secondary Amyloidosis in a Patient with Long Duration Crohn's

Secondary Amyloidosis in a Patient with Long Duration Crohn's

Unresolved issues in identifying and overcoming inadequate response

Unresolved issues in identifying and overcoming inadequate response

Anti-TNF therapy is associated with a reduction in radiation

Anti-TNF therapy is associated with a reduction in radiation

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease

Antisense inhibition of ICAM-1 expression as therapy provides

Antisense inhibition of ICAM-1 expression as therapy provides

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

Distinctive histopathologic phenotype in resection specimens from

Distinctive histopathologic phenotype in resection specimens from

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Are clinical trial data shared sufficiently today? Yes | The BMJ

Are clinical trial data shared sufficiently today? Yes | The BMJ

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's